ZNTL · XBRL financial data

Zentalis Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (ZNTL's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue from contracts with customers	0	0*	41	0	0	27*	0	0	0	0*	—	—
Research and development	47	52*	50	48	37	33*	27	28	23	29*	29	35
General and administrative	16	16*	16	17	15	40*	11	8	11	8*	9	9
Total operating expenses	63	68*	65	65	51	77*	46	36	34	37*	38	44
Operating income (loss)	(63)	(68)*	(25)	(65)	(51)	(50)*	(46)	(36)	(34)	(37)*	(38)	(44)
Income tax expense (benefit)	0	(0)*	0	0	(0)	(0)*	0	0	0	0*	0	0
Net income (loss)	(56)	(61)*	10	(88)	(40)	(47)*	(48)	(27)	(27)	(35)*	(35)	(42)
Earnings per share, basic USD per share	(0.79)	(0.86)*	0.14	(1.24)	(0.56)	(0.67)*	(0.67)	(0.37)	(0.37)	(0.49)*	(0.50)	(0.59)
Earnings per share, diluted USD per share	(0.79)	(0.86)*	0.14	(1.24)	(0.56)	(0.67)*	(0.67)	(0.37)	(0.37)	(0.49)*	(0.50)	(0.59)
Weighted average shares, basic millions of shares	71	71*	71	71	71	71*	72	72	72	72*	70	71
Weighted average shares, diluted millions of shares	71	71*	71	71	71	71*	72	72	72	72*	70	71

Fiscal quarters (ZNTL's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	111	28	38	37	41	34	42	38	39	36	32	25
Marketable securities	—	455	—	—	—	318	278	249	239	210	180	150
Accounts receivable	—	0	—	—	—	5	0	0	0	0	—	—
Prepaid and other current assets	12	14	15	13	9	10	10	8	8	7	6	7
Total current assets	528	497	504	440	400	386	343	312	288	253	218	181
Property and equipment, net	6	6	6	5	5	5	3	3	3	3	3	3
Right-of-use asset	36	36	35	33	33	33	32	31	30	26	26	25
Goodwill	4	4	4	4	4	0	—	—	—	—	—	—
Total assets	586	552	557	492	451	430	384	352	327	289	253	215
Accounts payable	14	15	11	20	8	7	8	4	7	7	7	8
Accrued liabilities	45	54	44	46	47	45	42	35	30	29	28	29
Total current liabilities	59	69	55	67	55	53	49	39	37	37	35	38
Lease liability, non-current	43	43	43	41	40	40	39	38	37	36	35	34
Total liabilities	104	114	99	109	96	93	89	77	74	73	70	72
Accumulated deficit	(828)	(889)	(878)	(967)	(1,007)	(1,054)	(1,103)	(1,130)	(1,156)	(1,191)	(1,227)	(1,269)
Total stockholders' equity	482	437	459	383	354	337	295	274	253	216	183	144
Total liabilities and equity	586	552	557	492	451	430	384	352	327	289	253	215
Common shares outstanding (cover page) millions of shares	71	71	71	71	71	72	72	72	72	71	71	72

Fiscal quarters (ZNTL's year ends in late December)

In millions of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	(56)	(61)*	10	(88)	(40)	(47)*	(48)	(27)	(27)	(35)*	(35)	(42)
Stock-based compensation	14*	14*	13	13*	10*	31*	6	6*	5*	3*	3	3*
Depreciation and amortization	0	0*	0	0	0	0*	0	0	0	0*	0	0
Net cash from operating activities	(39)*	(41)*	(52)	(35)*	(44)*	(40)*	(33)	(35)*	(27)*	(31)*	(33)	(37)*
Purchases of property and equipment	0*	0*	0	0*	0*	0*	0	0*	0*	0*	0	0*
Net cash from investing activities	(117)*	(42)*	62	34*	48*	32*	40	30*	28*	32*	30	30*
Proceeds from issuing common stock	0*	0*	—	—	0*	0*	—	—	—	year only	—	—
Share repurchases	—	year only	—	—	—	year only	—	—	—	year only	—	—
Net cash from financing activities	0*	0*	0	0*	0*	0*	0	0*	0*	(5)*	(1)	0*
Net change in cash	(156)*	(83)*	10	(1)*	4*	(7)*	8	(4)*	1*	(3)*	(4)	(7)*

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Zentalis Pharmaceuticals	25	not reported	(37)*	71.7M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings	23	not reported	(30)*	19.3M	4.0 quarters	Q2 FY26 10-QJun 30, 2026
Whitehawk Therapeutics	85	0	(15)*	57.0M	13.1 quarters	Q2 FY26 10-QJun 30, 2026
Veru	24	not reported	(5.5)*	17.1M	4.4 quarters	Q3 FY26 10-QJun 30, 2026
Lifevantage	15	42*	4.8*	12.5M	—	Q4 FY26 10-KJun 30, 2026
Medicinova	25	0.5	(1.9)*	49.2M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Seres Therapeutics	18	0.6	(10)*	10.2M	1.1 quarters	Q3 FY26 10-QSep 30, 2026
Oncolytics Biotech	4.1	not reported	(8.1)*	127.5M	0.5 quarters	Q2 FY26 10-QJun 30, 2026
Gyre Therapeutics	42	33	(4)*	115.3M	9.1 quarters	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 7, 2026, 12:32 PM ET. The filing on SEC.gov is the record.